Chadwick Pharmaceuticals

Chadwick Pharmaceuticals was a specialty pharmaceutical company based in Greenville, South Carolina, focused on developing topical delivery systems for established therapeutic agents. The company's primary focus was the development of CP-001, a topical formulation of a PDE5 inhibitor intended to treat erectile dysfunction while minimizing the systemic side effects associated with oral medications. Chadwick utilized the proprietary Z-pod delivery platform, a silica-based nanoparticle technology, through a strategic relationship with Zylö Therapeutics. In June 2021, Zylö Therapeutics acquired Chadwick Pharmaceuticals to fully integrate the CP-001 program into its internal pipeline. The acquisition aimed to accelerate the clinical development of topical treatments for sexual dysfunction and other localized conditions.